SAVOR trial results of Onglyza and CV Risk
AstraZeneca and Bristol-Myers Squibb Company have announced the full results of the SAVOR clinical trial in 16,492 adult patients with Type 2 Diabetes at high risk for Cardiovascular Events. In this study, Onglyza (saxagliptin) met the primary safety objective, demonstrating no increased risk for the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal ischemic stroke, when added to a patient�s current standard of care (with or without other anti-diabetic therapies), as compared to placebo. Onglyza did not meet the primary efficacy endpoint of superiority to placebo for the same composite endpoint. Patients treated with Onglyza experienced improved glycemic control and reduced development and progression of microalbuminuria over two years as assessed in exploratory analyses.
see -"Saxagliptin and Cardiovascular Outcomes"-September 2, 2013 | B.M. Scirica and Others (DOI: 10.1056/NEJMoa1307684)
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.